Company
Syndax
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
1
1 still marketed
Novel approvals
1
Approvals since 2021
2
Originals and new uses
Phase 3 trials
1
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
- Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 MutationPivotal-lookingRecruiting
Syndax PharmaceuticalsIndustry
NCT07211958 · 468 participants (planned) · Start Nov 25, 2025 · Primary completion Jun 2029
Drug: Revumenib; Placebo and 1 more · For: Acute Myeloid Leukemias
Sites: Goodyear, Arizona; Duarte, California; Farmington, Connecticut · 173 sites in all
Marketed drugs (1)
Newest FDA action first.
- Revuforj Revumenib Citrate · 2024
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.